How does a fractional CRO build a go-to-market strategy for a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He has sat on both sides of the fractional pricing conversation and can tell you in one call whether a retainer will actually pay for itself, because he has built the revenue math at scale rather than just modeled it on a slide.

👉 See Kory White on LinkedIn

The Buying Committee: Clinicians, Compliance, IT Security, and Finance - Each with Veto Power

The buying committee in healthcare technology is rarely fewer than six distinct roles, and the fractional CRO must map each member's specific evaluation criteria before any deal advances. The physician champion, typically a department head or chief medical information officer, evaluates the product based on clinical validity, peer-reviewed evidence, and workflow disruption - if the product requires nurses to change their documentation habits, the champion will kill the deal unless there is a clear reduction in administrative burden. The nursing informatics lead evaluates usability and training burden, because they are responsible for staff adoption and will veto any product that requires more than two hours of training per user. The compliance officer, who answers to the HIPAA privacy officer or the HITRUST assessor, requires documented evidence of data encryption at rest and in transit, breach notification protocols, and a signed business associate agreement before any demo occurs. The IT security architect runs independent penetration tests, reviews architecture diagrams for data residency compliance with state-specific laws like California's CCPA or New York's SHIELD Act, and will reject any product that uses a shared cloud instance without dedicated data segregation. The procurement manager enforces vendor credentialing requirements, which can include submitting a standardized security questionnaire (often the HITRUST CSF or the SIG Lite) and providing proof of cyber liability insurance with minimum coverage of $5 million. The finance director demands a hard-dollar ROI model that shows reduced readmissions, shortened length of stay, or avoided CMS penalties - for example, if the product reduces 30-day readmissions by 10% and each avoided readmission saves the hospital $15,000, the finance director will calculate the payback period and reject anything beyond 18 months.

The typical deal size ranges from $75,000 to $250,000 in annual recurring revenue for a single department or hospital, but can exceed $500,000 for enterprise-wide deployments across a multi-hospital health system. Budget approval is rarely a single fiscal event - most healthcare organizations operate on a July-to-June fiscal year, meaning budget is locked in by March for the following year, and any unplanned purchase requires a capital request that must be approved by a finance committee that meets quarterly. A fractional CRO must align pipeline targets to these fiscal cycles, not to calendar quarters, and must know the budget cycle of each target account before engaging. Deals stall most often at two points: the IT security review, which can take 60 to 90 days because the security team is understaffed and prioritizes existing vendor renewals over new evaluations, and the finance approval step, where the ROI model must be validated by a third-party consultant or a peer reference from a similar-sized health system. The fractional CRO cannot skip these stages; they must build a sales process that formally gates each step with documented deliverables - security questionnaires, ROI calculators, peer reference calls, and signed business associate agreements - before moving to the next committee member.

Sales-Cycle Implications: The Motion Forces a Stage-Gated, Slow Rhythm with Specific Leaks

The sales cycle in healthcare technology forces a motion that is the opposite of high-velocity SaaS. The average time from first contact to signed contract is 12 to 18 months, with 6 to 9 months of that spent in evaluation and procurement. This has direct implications for ramp time: a new fractional CRO should expect zero closed revenue in the first 90 days, and the first deal to close no earlier than month 6. Forecast behavior must be based on stage-gate progression, not weighted pipeline value, because a $200,000 deal that has only passed the clinical champion gate has a 10% probability of closing, while a deal that has passed the finance ROI approval gate has a 60% probability. A common leak is the "pilot trap" - the buyer asks for a free pilot with 20 users for six months, which consumes engineering resources for integration and training, and rarely converts because the pilot lacks formal procurement commitment and the champion often leaves during the pilot period. The fractional CRO must insist on a paid proof-of-concept with a minimum commitment of $25,000 and a defined evaluation period of 90 days, or reject the pilot entirely. Another leak is the "champion burnout" - the physician champion who drives the internal sale often leaves or gets reassigned to a different department, and without a backup sponsor, the deal dies because no other clinician has the authority or motivation to carry it forward. The fractional CRO must require a second clinical champion, often a nursing informaticist or a department administrator, before advancing to IT security review.

Pipeline shape is narrow and deep: a healthcare technology company with a $5 million annual target might need only 15 to 20 active opportunities at any time, each with a $200,000 average deal size, but each requiring 40 to 60 touches across the committee over the cycle. The fractional CRO should expect a 20% to 30% win rate on qualified opportunities, meaning they need 5 to 7 times coverage in early-stage pipeline to hit annual targets. A specific leak that fractional CROs miss is the "regulatory drift" - a deal that has been in evaluation for 12 months may suddenly become irrelevant because a new CMS rule changes the reimbursement landscape, and the buyer no longer prioritizes the problem the product solves. The fractional CRO must conduct a quarterly regulatory landscape review and flag any deal that has been in evaluation for more than 9 months without moving to the finance gate. Another leak is the "vendor credentialing black hole" - some health systems require vendors to complete a credentialing process through a third-party platform like Symplr or VendorMate, which can take 90 days just to get approved as a vendor before any sales conversation can start. The fractional CRO must identify these requirements before engaging and factor the credentialing timeline into the sales cycle forecast.

First 90 Days: Audit Compliance Readiness, Map Budget Cycles, and Build the Regulatory Narrative

A fractional CRO in healthcare technology does not start with a sales blitz. The first 30 days are a forensic audit of the existing pipeline, customer references, and product-market fit documentation. They must review every open opportunity for three things: whether the buyer has a formal procurement process (e.g., an RFP or a vendor credentialing requirement through Symplr or VendorMate), whether the product has completed a HITRUST or SOC 2 Type II audit, and whether the sales team has documented ROI models for at least three customer segments (e.g., acute care hospitals with 200-500 beds, ambulatory surgery centers, and telehealth platforms). Without these, the fractional CRO cannot build a credible GTM motion because the compliance and finance gates will reject the deal. Days 31 to 60 are about aligning the product roadmap with regulatory milestones. If the product lacks a HIPAA business associate agreement template, a data residency policy for state-specific laws, or a SOC 2 report, the fractional CRO must push engineering to deliver these before any new sales activity. They must also audit the existing customer contracts to ensure every customer has signed a valid business associate agreement - if not, the company is at risk of HIPAA violations that could kill future deals.

Days 61 to 90 are spent building a "regulatory narrative" - a one-page document that maps the product's features to specific compliance requirements, such as "Our audit log satisfies CMS Conditions of Participation for Conditions of Participation §482.24 for medical record documentation" or "Our encryption protocol meets the HITRUST CSF requirement for data at rest." The fractional CRO must also build a "financial narrative" that shows a 3:1 ROI within 18 months for a typical health system, using specific CMS penalty data - for example, the Hospital Readmissions Reduction Program imposes penalties of up to 3% of Medicare payments for hospitals with excess readmissions, and the product reduces readmissions by 10%, which translates to $500,000 in avoided penalties for a 300-bed hospital. The fractional CRO must also conduct a "champion audit" - calling every lost deal from the past 12 months to understand why the champion left, whether the budget was pulled due to a fiscal year change, or whether the product failed the IT security review. The output of the first 90 days is a revised ICP that is narrower than the company's previous one: for example, "health systems with 200-500 beds in states with mandatory value-based care programs like Maryland or Massachusetts" rather than "all hospitals," and "ambulatory surgery centers with at least 10 operating rooms" rather than "all outpatient facilities."

Operating Cadence: Weekly Pipeline Reviews by Gate, Monthly Committee Mapping, Quarterly Regulatory Updates

The fractional CRO's operating cadence must be more structured than in other industries because the sales cycle is long and the risk of drift is high. Weekly pipeline reviews should focus on the movement of deals through four specific gates: Gate 1 - Clinical Champion Confirmed, with a documented letter of support or a meeting summary signed by the champion; Gate 2 - IT Security Questionnaire Submitted, with a copy of the completed questionnaire and the date it was submitted; Gate 3 - Compliance Review Scheduled, with a meeting confirmation from the compliance officer or a completed vendor credentialing profile; and Gate 4 - Finance ROI Approved, with a signed ROI worksheet or a budget approval email from the finance director. The fractional CRO should not allow deals to sit in a gate for more than 30 days without a documented reason, and any deal that has been in Gate 1 for more than 60 days should be moved to "stalled" and deprioritized until the champion re-engages.

Monthly reviews include a "committee mapping" exercise for each deal: a visual chart showing each committee member, their known objections, and the next action to address them. For example, if the IT security architect is concerned about data residency, the next action is to provide a data center location map and a data flow diagram. If the finance director is skeptical about the ROI model, the next action is to schedule a peer reference call with a similar-sized health system that has achieved the claimed ROI. This is not a generic CRM update; it is a specific, handwritten map that the fractional CRO reviews with the sales team to ensure no committee member is being ignored. Quarterly updates involve a regulatory landscape review: new state laws, CMS rule changes, or payer policy shifts that affect the product's value proposition. For example, if CMS introduces a new penalty for hospital-acquired conditions related to a specific condition the product addresses, the fractional CRO must update the ROI model and retrain the team within two weeks. The fractional CRO also owns the executive sponsor relationship with the CEO and board, providing a monthly dashboard that shows pipeline velocity by gate, not just total value. A typical dashboard might show: "Gate 1 (Champion Confirmed): 12 deals, $2.4M; Gate 2 (Security Submitted): 6 deals, $1.2M; Gate 3 (Compliance Scheduled): 3 deals, $600K; Gate 4 (ROI Approved): 1 deal, $200K." The dashboard also includes a "regulatory risk" section that flags any new laws or rules that could affect the pipeline, such as a state data privacy law that requires new data residency commitments.

What the Fractional CRO Owns vs. Advises: A Clear Operational Boundary

The fractional CRO in healthcare technology must draw a clear line between what they own operationally and what they advise strategically. They own the sales process, including the stage-gate definitions, the deal desk for pricing and discounting, and the monthly forecast. They own the hiring and coaching of the sales team, including the development of a "clinical sales playbook" that trains reps on how to speak with physicians versus IT versus finance - for example, a rep should never use the word "algorithm" with a clinician because it implies black-box decision-making; instead, they should say "clinical decision support tool based on peer-reviewed evidence." They own the customer reference program, because in healthcare, a reference call with a similar-sized health system is often the deciding factor in a deal - the fractional CRO must maintain a list of at least 10 referenceable customers across different segments and ensure they are willing to take calls within 48 hours.

They advise on product roadmap priorities, but they do not own them - they must advocate for features that shorten the sales cycle, such as automated HIPAA compliance reports or pre-built integrations with Epic and Cerner, but cannot force engineering to build them. They advise on pricing strategy, but the final pricing authority rests with the CEO - the fractional CRO should recommend a value-based pricing model tied to per-bed or per-encounter metrics, but the CEO must approve any deviation from the standard price book. They advise on channel partnerships with EHR vendors like Epic, Cerner, or Meditech, or with consulting firms like the Advisory Board or Huron, but they do not manage those relationships day-to-day unless explicitly contracted to do so. A critical distinction: the fractional CRO should never act as a full-time salesperson. If the company expects them to carry a personal quota and close deals, the engagement model is broken. Their value is in systemizing the revenue process, not in being the top rep. The signal to convert to full-time is when the company has achieved three consecutive quarters of predictable pipeline generation and at least $2 million in annual recurring revenue from the new GTM motion, and when the fractional CRO is spending more than 60% of their time on strategic planning rather than operational firefighting.

Signals to Convert to Full-Time or End the Engagement: Milestones, Not Time

The decision to convert a fractional CRO to full-time in a healthcare technology company is not based on time elapsed but on specific milestones. The first signal is when the company has a repeatable sales process that survives the departure of the fractional CRO - meaning the sales team can independently move deals through the four gates without daily oversight, and the stage-gate definitions are documented in a playbook that a new hire can follow. This typically takes 12 to 18 months. The second signal is when the company has at least three referenceable customers in the same ICP segment, and those customers are willing to participate in reference calls and case studies without requiring a personal relationship with the fractional CRO. The third signal is when the company has achieved a 12-month trailing win rate above 25% on qualified opportunities, and the average sales cycle has shortened by at least 20% from the baseline at the start of the engagement - for example, from 15 months to 12 months. The fourth signal is when the company has a clear path to $10 million in annual recurring revenue, and the fractional CRO is the natural person to lead that growth because they have built the relationships with key health systems and understand the regulatory landscape.

Conversely, the engagement should end or be restructured if after 12 months the company has not closed a single deal above $100,000, or if the product has not achieved the necessary compliance certifications (SOC 2, HITRUST, HIPAA BA agreement), or if the CEO is unwilling to invest in the sales team headcount needed to support the pipeline. A fractional CRO should also exit if the company pivots to a different buyer without adjusting the GTM strategy - for example, from health systems to payers - because the buying committee and sales cycle change entirely, and the fractional CRO's expertise in hospital procurement is no longer relevant. The cleanest exit is a 90-day transition period where the fractional CRO documents every process, trains a successor (either internal or a new full-time CRO), and hands off the pipeline with a detailed deal-by-deal transition plan that includes the status of each gate, the next action for each committee member, and the regulatory risks for each deal.

FAQ

How do you handle a physician champion who leaves mid-cycle? Immediately pause the deal and ask the health system's procurement team to identify a replacement clinical sponsor, such as the department vice chair or the nursing informatics lead. Do not assume the deal can continue without a physician champion, because the compliance and finance gates will not advance without clinical validation. If no replacement is named within 30 days, the deal should be moved to a "stalled" stage and deprioritized, and the fractional CRO should reallocate resources to other opportunities. To prevent this, the fractional CRO should build a backup champion strategy into every deal from the start, requiring the initial champion to identify a second clinical advocate, such as a nurse manager or a quality improvement director, before the deal moves to IT security review.

What is the most common mistake fractional CROs make in healthcare technology? They treat the sales cycle like a standard B2B SaaS deal and try to accelerate it with demos and free trials, skipping the compliance and security gates. This causes the deal to collapse at the finance approval stage because the health system's legal team rejects the contract due to missing business associate agreements or inadequate data security documentation. The correct approach is to front-load the regulatory validation: have the product's SOC 2 report, HIPAA BA agreement, data residency policy, and cyber liability insurance certificate ready before the first meeting, and require the buyer to sign a mutual NDA and a data processing agreement before any product demo. This may slow the initial engagement, but it prevents the deal from stalling at the legal review stage six months later.

How do you price a healthcare technology product when the buyer is a health system? Pricing should be based on a value metric that aligns with the buyer's financial incentives, such as per-bed, per-encounter, or per-readmission avoided. Avoid per-seat pricing because health systems have thousands of employees and will push for enterprise discounts that destroy unit economics. The fractional CRO should build a pricing model that shows a 3:1 ROI within 18 months, and then anchor the price to that ROI calculation. For example, if the product reduces readmissions by 10% and each avoided readmission saves the hospital $15,000, and the hospital has 1,000 readmissions per year, the total savings is $1.5 million. The price should be no more than $500,000 per year, or $500 per avoided readmission. The fractional CRO must also offer a tiered pricing structure for different hospital sizes - for example, $75,000 for hospitals with 100-200 beds, $150,000 for 200-500 beds, and $300,000 for 500+ beds.

What do you do if the product has no compliance certifications yet? Do not attempt to sell to health systems, because the compliance and IT security gates will reject the deal before it reaches finance. Instead, target smaller buyers like physician groups with fewer than 50 providers, ambulatory surgery centers with fewer than 5 operating rooms, or telehealth startups that have less stringent compliance requirements because they are not subject to CMS Conditions of Participation. Use those initial customers to build the reference cases and revenue needed to fund the SOC 2 and HITRUST audits, which typically cost $50,000 to $100,000 and take 6 to 12 months. The fractional CRO must communicate to the CEO that selling to health systems without these certifications will result in a 90% rejection rate and burned relationships that make future sales harder. The GTM strategy must be segmented: a "land" motion for smaller, less regulated buyers with a 6-month sales cycle and $25,000 average deal size, and an "expand" motion for health systems once certifications are in place, with a 12-month sales cycle and $200,000 average deal size.

Sources